Download PDF
CC BY-NC-ND 4.0 · J Lab Physicians 2019; 11(04): 323-329
DOI: 10.4103/JLP.JLP_76_19
Original Article

Evaluation of prognostic utility of Ki-67, P53, and O-6-methylguanine-DNA methyltransferase expression in pituitary tumors

Chhanda Das
Department of Pathology, IPGME and R, Kolkata, West Bengal, India
,
Pratap Mondal
Department of Pathology, IPGME and R, Kolkata, West Bengal, India
,
Madhumita Mukhopadhyay
Department of Pathology, IPGME and R, Kolkata, West Bengal, India
,
Satinath Mukhopadhyay
Department of Endocrinology, IPGME and R, Kolkata, West Bengal, India
,
Ipsita Ghosh
Department of Endocrinology, IPGME and R, Kolkata, West Bengal, India
,
Anusha Handral
Department of Endocrinology, IPGME and R, Kolkata, West Bengal, India
› Author Affiliations Financial support and sponsorship Nil.
› Further Information
  PDF Download Permissions and Reprints

Abstract

BACKGROUND OR CONTEXT: Pituitary adenoma (PA) is the most common pathology of the pituitary gland. Pituitary tumors were historically considered benign, however, from recent advances in pathological and molecular analyses, numerous prognostic markers have been identified, allowing a better characterization of tumor behavior and prediction of response to treatment and recurrences.

AIMS AND OBJECTIVES: Evaluation of the epidemiological occurrence of pituitary tumors in our center and prediction of the benign, aggressive, or malignant nature of the tumor with the help of immunohistochemical markers (IHC) Ki-67, P53, and O-6-methylguanine-DNA methyltransferase (MGMT) along with radiology.

MATERIALS AND METHODS: A prospective study was done in 33 cases. Patients with clinically suspected pituitary tumors and related symptoms and signs are referred from the endocrine outpatient department and subsequently operated at the neurosurgery department were selected. We have studied the clinical features, radiology, histopathology, and IHC with the help of Ki-67, P53, and MGMT of PA over 2 years.

RESULTS: We have 94% (31/33) cases of PA among them 94% (29/31) cases are macroadenoma. The IHC was conducted on 30 cases (excluding 1 case of pituitary apoplexy) where Ki-67, p53, and MGMT have been used for IHC in order to analyze the prognosis of the PA, irrespective of the immunological subtype of the PA. In our study, only 13% (4 patients) had MGMT score 0 and 2 patients, among these 4 patients having above cutoff level of Ki-67 and p53 value, considered as aggressive (in case of Ki-67 >3% and >50% in case of p53). When comparing MGMT expression with recurrence, a high degree of significance was found (Mann–Whitney U-test, P = 0.0038). Most of the recurrent tumors (6/9) had MGMT score 1 or below and most of the nonrecurring tumor had MGMT score 2 or above. When comparing MGMT expression with aggressiveness, a high degree of significance was found (Mann–Whitney U-test, P < 0.0001). Finally, combining the radiological Ki-67, p53, and MGMT values, two cases of aggressive adenoma have been seen in our study, the remaining being benign adenomas (WHO classification 2004). We did not encounter any case of pituitary carcinoma. MGMT did not show any significant correlation with radiological grading and histology.

CONCLUSION: The benign, aggressive, or malignant nature of PA can be effectively predicted with the help of IHC, such as Ki-67, p53, and MGMT. This helps in better patient management and predicts recurrences and prognosis.

Key words

Immunohistochemistry - Ki-67 - O-6-methylguanine-DNA methyltransferase - P53


Publication History

Received: 30 April 2019

Accepted: 16 November 2019

Article published online:
07 April 2020

© 2019.

Thieme Medical and Scientific Publishers Private Ltd.
A-12, Second Floor, Sector -2, NOIDA -201301, India

 

  • References

  • 1 Gold EB. Epidemiology of pituitary adenomas. Epidemiol Rev 1981;3:163-83.
  • 2 Lopes MB. Tumors of the pituitary gland. In: Fletcher CD, editor. Diagnostic Histopathology of Tumors. 4th ed., Ch. 17. Philadelphia, PA, USA: Elsevier Saunders; 2013. p. 1146.
  • 3 Patel YC, Ezzat S, Chik CL, Rorstad OP, Serri O, Ur E, et al. Guidelines for the diagnosis and treatment of acromegaly: A Canadian perspective. Clin Invest Med 2000;23:172-87.
  • 4 Chatzellis E, Alexandraki KI, Androulakis II, Kaltsas G. Aggressive pituitary tumors. Neuroendocrinology 2015;101:87-104.
  • 5 Lloyd RV, Kovacs K, Young WF Jr., Farrell WE, Asa SL, Trouillas J, et al. Tumours of the pituitary. In: DeLellis Ronald A, Lloyd RV, Heitz Philipp U, Charis E, editors. WHO Classification of Tumours – Tumours of Endocrine Organs. 3rd ed. France, Lyon: IARC Press; 2004. p. 12.
  • 6 Mellai M, Caldera V, Annovazzi L, Chiò A, Lanotte M, Cassoni P, et al. MGMT promoter hypermethylation in a series of 104 glioblastomas. Cancer Genomics Proteomics 2009;6:219-27.
  • 7 Hadzhiyanev A, Ivanova R, Nachev E, Elenkova A, Yaneva M, Zaharieva S, et al. Evaluation of prognostic utility of MIB-1 and p53 expression in pituitary adenomas: Correlations with clinical behaviour and follow-up results. Biotechnol Biotechnol Equip 2014;28:502-7.
  • 8 Radhakrishnan K, Mokri B, Parisi JE, O'Fallon WM, Sunku J, Kurland LT. The trends in incidence of primary brain tumors in the population of Rochester, Minnesota. Ann Neurol 1995;37:67-73.
  • 9 Saeger W, Lüdecke DK, Buchfelder M, Fahlbusch R, Quabbe HJ, Petersenn S. Pathohistological classification of pituitary tumors: 10 years of experience with the German Pituitary Tumor Registry. Eur J Endocrinol 2007;156:203-16.
  • 10 Mahta A, Haghpanah V, Lashkari A, Heshmat R, Larijani B, Tavangar SM. Non-functioning pituitary adenoma: Immunohistochemical analysis of 85 cases. Folia Neuropathol 2007;45:72-7.
  • 11 Rishi A, Sharma MC, Sarkar C, Jain D, Singh M, Mahapatra AK, et al. A clinicopathological and immunohistochemical study of clinically non-functioning pituitary adenomas: a single institutional experience. Neurol India 2010;58:418-23.
  • 12 Kleinschmidt-DeMasters BK. Pituitary gland. In: Rosai J, editor. Rosai and Ackerman's Surgical Pathology. 10th ed., Ch. 29. Milan, Italy: Elsevier Inc.; 2011. p. 2441-66.
  • 13 Kanter SL, Mickle JP, Hunter SB, Rhoton AL. Pituitary adenomas in pediatric patients: Are they more invasive? Pediatr Neurosci 1985;12:202-4.
  • 14 Osamura RY, Kajiya H, Takei M, Egashira N, Tobita M, Takekoshi S, et al. Pathology of the human pituitary adenomas. Histochem Cell Biol 2008;130:495-507.
  • 15 Ortiz-Plata A, Tena-Suck ML, Pérez-Neri I, Rembao-Bojórquez D, Fernández A. Pituitary Adenomas – Clinico-Pathological, Immunohistochemical and Ultrastructural Study. Adenomas P, Movaghar VR, Ed. 6, InTech. Chapter 4, Rijeka, Croatia 2012.
  • 16 Dai C, Sun B, Liu X, Bao X, Feng M, Yao Y, et al. O-6-Methylguanine-DNA methyltransferase expression is associated with pituitary adenoma tumor recurrence: a systematic meta-analysis. Oncotarget 2017;8:19674-83.
  • 17 Thapar K, Kovacs K, Scheithauer BW, Stefaneanu L, Horvath E, Pernicone PJ, et al. Proliferative activity and invasiveness among pituitary adenomas and carcinomas: An analysis using the MIB-1 antibody. Neurosurgery 1996;38:99-106.
  • 18 Salehi F, Agur A, Scheithauer BW, Kovacs K, Lloyd RV, Cusimano M. Ki-67 in pituitary neoplasms: A review – Part I. Neurosurgery 2009;65:429-37.
  • 19 Thapar K, Scheithauer BW, Kovacs K, Pernicone PJ, Laws ER Jr. P53 expression in pituitary adenomas and carcinomas: Correlation with invasiveness and tumor growth fractions. Neurosurgery 1996;38:765-70.
  • 20 Lloyd RV, Osamura Robert Y. Tumours of the pituitary. In: Kloppel G, Rosai J, editors. WHO Classification of Tumours – Tumours of Endocrine Organs. 4th ed. France, Lyon: IARC Press; 2017. p. 18.